CMS issues guidance on coverage for COVID-19 tests

By LabPulse.com staff writers

April 13, 2020 -- The U.S. Centers for Medicare and Medicaid Services (CMS) and the Departments of Labor and the Treasury on April 11 issued guidance regarding expanded coverage of COVID-19 diagnostic testing, including antibody testing, for Americans with private health insurance.

The move is an effort to mitigate financial barriers Americans may face to receiving COVID-19 testing and health services, CMS said.

Representatives of major health insurance companies met with President Trump in March and offered to cover COVID-19 testing without cost-sharing measures such as co-pays, according to CMS. The expanded coverage is part of the implementation of the Families First Coronavirus Response Act (FFCRA) and Coronavirus Aid, Relief, and Economic Security (CARES) Act, which requires private health issuers and employer group health plans to cover COVID-19 testing with no out-of-pocket expenses, the agency explained.

"It is critical that Americans have peace of mind knowing that cost won't be a barrier to testing during this national public health emergency," CMS Administrator Seema Verma said in a statement. "[This] action under the leadership of President Trump allows millions of Americans to access the vital health services they need to fight COVID-19, including antibody testing once it becomes widely available."

What are the risks of false-negative COVID-19 tests?
Are healthcare providers and the public putting too much faith in the accuracy of diagnostic tests for COVID-19? An article published April 9 in Mayo...
Testing delays hamper hospitals in COVID-19 response
Delays and supply shortages of diagnostic tests for COVID-19 are having a ripple effect on the response of U.S. hospitals to the COVID-19 pandemic, according...
It's time to recruit research labs in the COVID-19 fight
Careful incorporation of research laboratories into the COVID-19 testing effort could increase capacity in the U.S. and globally, writes molecular diagnostics...
Can the reality of coronavirus antibody tests live up to hype?
It's easy to see the appeal a rapid antibody test for the novel coronavirus would have in the imagination of the general public. Results come in a matter...
Did BodySphere jump the gun on '2-minute' COVID-19 test?
The news seemed too good to be true: A company called BodySphere claimed to have received emergency use authorization from the U.S. Food and Drug Administration...

Copyright © 2020 LabPulse.com

Last Updated np 4/13/2020 11:24:57 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current